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Objective: We sought to evaluate the use of video-assisted thoracoscopy among patients with lung cancer and its
safety and effectiveness relative to conventional resection.
Methods:A cohort study (1994–2002) was conducted by using the Surveillance, Epidemiology, and End-Results
Medicare database. Video-assisted thoracoscopy and conventional resection were hypothesized to be equivalent
in terms of risks of death. Equivalency was defined by a confidence interval of 0.72 to 1.28 for the odds of 30-day
death and 0.89 to 1.11 for the hazard of death, corresponding to a difference of no more than 1% for 30-day mor-
tality and 5% for 5-year survival, respectively.
Results: Among 12,958 patients who underwent segmentectomy or lobectomy (mean age, 74  5 years), 6%
underwent video-assisted thoracoscopy. The use of video-assisted thoracoscopy increased from 1% to 9% be-
tween 1994 and 2002. Compared with those who underwent conventional resection, patients who underwent
video-assisted thoracoscopy more frequently had smaller tumors (P<.001) and stage I disease (P¼ .03), under-
went lymphadenectomy (P< .001), and were cared for by higher-volume surgeons (P< .001) and at higher-
volume hospitals (P< .001). After adjusting for differences in patient, cancer, management, and provider char-
acteristics, the odds of early death were not significantly different between patients undergoing video-assisted
thoracoscopy and those undergoing conventional resection, although equivalency was not demonstrated (adjusted
odds ratio, 0.93; 95% confidence interval, 0.57–1.50). The hazard of death was equivalent for video-assisted thor-
acoscopy and conventional resection (adjusted hazard ratio, 0.99; 95% confidence interval, 0.90–1.08).
Conclusions: Video-assisted thoracoscopy was uncommonly used to manage lung cancer, although its use has
increased over time. Video-assisted thoracoscopy and conventional resection were equivalent in terms of long-
term survival.
Farjah et al General Thoracic SurgeryAlthough an increasing body of evidence supports the use of
video-assisted thoracoscopy (VATS) in lung cancer man-
agement,1-16 it is unclear how widely it is being used. Addi-
tionally, it is unknown whether the safety and effectiveness
of this relatively new procedure is equivalent to that of open
thoracotomy.
New technology and therapeutic interventions can offer
advantages over standard treatment without compromising
well-established safety and efficacy benchmarks, but deter-
mining whether 2 competing therapies are equivalent is
methodologically challenging. Standard hypothesis testing
cannot prove equivalence, even when the outcomes of 2
treatments are not significantly different. A well-accepted
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domized trial: a study designed to rule out the possibility
of prespecified, clinically important differences in outcomes
between treatment groups.17 Because the feasibility of a ran-
domized trial of VATS versus conventional resection has
been questioned, a noninferiority-based analysis of observa-
tional data might be informative.
Using a nationally representative tumor registry linked to
Medicare claims and a noninferiority-based analytic frame-
work, we described the use and associated outcomes of
VATS among patients with lung cancer who underwent seg-
mentectomy or lobectomy. We hypothesized that the safety
(30-day case fatality) and effectiveness (long-term survival)
of VATS and conventional resection would be equivalent.
Clinically important differences of 1% for 30-day case fatal-
ity and 5% for 5-year survival were specified a priori.
MATERIALS AND METHODS
The Surveillance, Epidemiology, and End-Results (SEER) Medicare
database was used to perform a retrospective cohort study of patients given
diagnoses of lung cancer from 1994 through 2002. SEER captures approx-
imately 14% of incident malignancies in the United States. Tumor registry
data have been linked to claims data among SEER patients who were Medi-
care beneficiaries. The utility, quality, and validity of the SEER-Medicare
database have been described previously.18 The University of Washington
Institutional Review Board approved this study and waived consent.
Among 191,024 patients given diagnoses of lung cancer from 1994
through 2002, the following sequential exclusions were made: patientsrdiovascular Surgery c Volume 137, Number 6 1415
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SAbbreviations and Acronyms
CI ¼ confidence interval
HCPCS ¼ Healthcare Common Procedure
Coding System
LOS ¼ length of stay
SEER ¼ Surveillance, Epidemiology,
and End-Results
VATS ¼ video-assisted thoracoscopy
given diagnoses at autopsy/death (n¼ 4379), patients who did not undergo
segmentectomy or lobectomy (n¼ 170,258), patients less than 66 years old
(n¼ 1370), diagnosis of a second malignancy between 3 months before and
6 months after lung cancer diagnosis (n ¼ 812), and patients with only part
A or part B, concurrent health maintenance organization enrollment, or both
between 1 year before and 6 months after lung cancer diagnosis (n¼ 1247).
These exclusions were made to ensure the accuracy and completeness of
claims data when used for the purposes of research, and the specific reasons
for the exclusions have been described previously.19
Outcomes included long-term survival, death within 30 days of the op-
eration, length of stay (LOS), and Medicare expenditures. Death data
were available through the Medicare Enrollment Database with follow-up
through 2005. LOS and Medicare expenditure information were available
from the Medicare Provider Analysis and Review file. Costs were defined
by the actual dollar amount paid by Medicare to the hospital (expenditures)
rather than hospital charges and adjusted for inflation by using the Con-
sumer Price Index for Medical Care.
Patient and disease characteristics were available through the SEER reg-
istry, and management and provider information was available through
Medicare claims. Indicators of low income or education were based on
the lowest quartiles of median income and proportion with a high-school ed-
ucation within a given zip code. Geography was defined by the SEER reg-
istry where the patient was diagnosed. Residence refers to the population
size of the area where the patient lived. Claims within the carrier and outpa-
tient files in the year before diagnosis were used to ascertain the Klabunde-
modified Charlson Comorbidity Index.20 Tumor size, stage (American Joint
Committee on Cancer, sixth edition), and histology were based on all avail-
able information within 4 months of diagnosis. The use of mediastinal stag-
ing modalities was ascertained by using claims defined by the Healthcare
Common Procedure Coding System (HCPCS) and present within the carrier
claims files, outpatient files, or both. Resection type, radiation therapy, and
chemotherapy were defined by using the carrier claim files with relevant
HCPCS; by using the outpatient files with relevant HCPCS codes, Interna-
tional Classification of Diseases (Ninth Revision) procedure codes, and
Revenue Center Codes (Appendix 1); or both. Hospital teaching status
was determined by linkage to Medicare hospital files. Volume measure-
ments reflected average yearly provider volume among SEER-Medicare pa-
tients but not total provider volume.21 A dichotomous variable was created
to indicate higher-volume providers based on those within the highest quar-
tile of volume.
STATA (Special Edition 9.2; StataCorp, College Station, Tex) was used
for all statistical analyses. Continuous and categorical variables were
compared by using a t test for independent samples and the c2 test, respec-
tively. The Kaplan–Meier method was used to obtain unadjusted survival
estimates. A priori designated potential confounders included patient (age,
sex, race, and comorbidity index), cancer (stage, histology, and tumor
size), management (mediastinoscopy, mediastinal lymphadenectomy, and
neoadjuvant therapy), and provider (surgeon volume and hospital volume
and teaching status) characteristics. The analytic strategy was to sequen-
tially add groups of variables to regression models to better understand
how these variables might confound unadjusted comparisons. Cox propor-1416 The Journal of Thoracic and Cardiovascular Stional-hazards models were used to evaluate the relationship between ap-
proach to resection and overall survival while providing adjustment for
potential confounders. Survival time was defined as the interval between
the date of diagnosis and the date of death or censoring. The propor-
tional-hazards assumption was tested by using Schoenfeld residuals. In
the event the assumption was not satisfied, extended (stratified) Cox regres-
sion models were used. Logistic regression models were used to examine
the relationship between approach to resection and 30-day mortality while
providing adjustment for potential confounders. Linear regression was
used to evaluate the relationship between approach to resection and LOS
and expenditures while providing adjustment for potential confounders.
Because the distributions of LOS and expenditures were not normal,
both variables were log transformed, and geometric means were reported.
All multivariable regression models adjusted for clustering at the hospital
level.
Confidence interval (CI) inspection was used to conduct a noninferior-
ity-based analysis. Because regression models estimate relative risk, pre-
specified noninferiority risk differences were expressed in terms of
relative risk by using the conventional resection group’s outcomes as base-
line. CIs defining equivalence were 0.72 to 1.28 for the odds of early death
and 0.89 to 1.11 for the hazard of death, corresponding to a difference of
no greater than 1% for 30-day mortality and 5% for 5-year survival, re-
spectively. Derived CIs falling within these ranges indicated equivalence.
If the upper bounds of the derived CIs exceeded the upper bounds of the
predetermined equivalency intervals, then inferiority could not be ex-
cluded. Similarly, if the lower bounds of derived CIs exceeded the lower
bounds of prespecified equivalency intervals, then superiority could not
be excluded.
RESULTS
Between 1994 and 2002, 12,958 patients with lung cancer
underwent segmentectomy or lobectomy performed by 1600
surgeons at 781 hospitals. Six percent of patients underwent
VATS resection by 7% of surgeons and at 13% of hospitals.
The frequency of VATS use increased over time among
patients, surgeons, and hospitals (Figure 1).
Patients who underwent VATS or open resection were
dissimilar in many ways (Table 1). Compared with patients
who underwent conventional resection, those who under-
went VATS were older (76 vs 74 years, P< .001); more
commonly lived in the West (61% vs 42%, P< .001) or
FIGURE 1. Temporal trends in the use of video-assisted thoracoscopy
(VATS) among patients, surgeons, and hospitals.urgery c June 2009
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STABLE 1. Patient and disease characteristics by approach to resection
All
(n ¼ 12,958)
Open
(n ¼ 12,237)
Thoracoscopic
(n ¼ 721)
P
value*
Age, y (%) <.001
66–70 27 27 21
71–75 34 34 32
76–80 26 26 28
81–85 11 11 16
86þ 2 2 5
Mean  SD 74  5 74  5 76  6 <.001
Male sex (%) 51 51 45 .01
Race (%) .10
White 89 89 92
Black 5 5 4
Other 5 5 5
Missing <1 <1 <1
Income (%) <.001
Lowest quartile 24 24 14
Missing 4 4 3
Education (%) <.001
Lowest quartile 24 24 18
Missing 4 4 3
Marital status (%) <.001
Unmarried 38 38 41
Missing 4 4 1
Geography (%) <.001
West 43 43 61
East 21 21 33
Midwest 23 23 4
South 13 13 2
Residence (%) <.001
Metropolitan 87 87 96
Urban 6 6 2
Rural 8 8 2
Prior malignancy (%) 23 23 29 <.001
Comorbidity index (%) .40
0 54 54 52
1 30 30 30
2 11 11 11
3 6 6 7
Histology (%) <.001
NSCLC
Adenocarcinoma 56 56 64
Squamous 29 29 23
Large cell 5 5 3
Undifferentiated 2 2 2
NOS 3 3 2
SCLC 1 2 1
Other 4 4 5
Stage (%) .01
I 61 61 65
II 12 12 9
IIIA 7 7 5
IIIB 4 4 6
IV 3 3 4
Missing 13 13 11The Journal of Thoracic and Cametropolitan areas (96% vs 86%, P< .001); more com-
monly had a prior malignancy (29% vs 22%, P< .001),
stage I disease (65% vs 61%, P ¼ .03), or adenocarcinoma
(64% vs 55%, P< .001); and were less frequently in low-
income (14% vs 25%, P< .001) or low-education (18%
vs 24%, P< .001) strata. The mean tumor size was signif-
icantly smaller among patients who underwent VATS (2.8
vs 3.4 cm, P<.001). No significant differences in the distri-
bution of race or comorbidity index were observed.
Perioperative management varied by approach to resec-
tion (Table 2). Compared with those in the conventional
resection group, patients in the VATS group more often un-
derwent mediastinal lymphadenectomy (45% vs 26%, P<
.001) and neoadjuvant therapy (8% vs 6%, P< .001). Dur-
ing the period when claims for positron emission tomogra-
phy were available (1998–2002), patients undergoing
VATS more often underwent positron emission tomography
(51% vs 29%, P<.001). Those in the VATS group less fre-
quently received adjuvant therapy (15% vs 20%,
P< .001). There was no significant difference in the use
of mediastinoscopy between groups.
Provider characteristics also varied by approach to resec-
tion (Table 2). Compared with those who underwent con-
ventional resection, patients who underwent VATS were
cared for by a higher proportion of higher-volume surgeons
(92% vs 75%, P<.001) and more frequently at higher-vol-
ume (88% vs 75%, p<0.001) and teaching (84% vs 63%,
P< .001) hospitals.
In the unadjusted analysis VATS was associated with sig-
nificantly higher 5-year overall survival rates compared with
those after conventional resection (48% vs 44%, P ¼ .02),
although 30-day mortality rates were not significantly differ-
ent (3.2% vs 3.6%, P ¼ .53). VATS was associated with
shorter LOS (4 vs 8 days, P<.001) but higher Medicare ex-
penditures ($20,519 vs $19,786, P ¼ .008).
TABLE 1. Continued
All
(n ¼ 12,958)
Open
(n ¼ 12,237)
Thoracoscopic
(n ¼ 721)
P
value*
Size
Mean  SD, cm 3.3  2.0 3.3  2.0 2.8  1.6 <.001
>3 cm (%) 40 41 29 <.001
Missing (%) 5 5 3
Location (%) .16
RUL 31 31 31
RML 5 5 5
RLL 18 18 18
LUL 28 29 28
LLL 15 16 15
Missing 3 3 3
SD, Standard deviation; NSCLC, non–small cell lung cancer; NOS, histology not oth-
erwise specified; SCLC, small cell lung cancer; RUL, right upper lobe; RML, right mid-
dle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe. *P value for
tests comparing thoracoscopic and open resection.rdiovascular Surgery c Volume 137, Number 6 1417
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STABLE 2. Management and provider characteristics by approach to resection
All (n ¼ 12,958) Open (n ¼ 12,237) Thoracoscopic (n ¼ 721) P value*
Staging (%)
PETy 30 30 51 <.001
Mediastinoscopy 16 16 17 .49
Neoadjuvant therapy (%) 6 6 8 <.001
Mediastinal lymphadenectomy (%) 27 26 45 <.001
Adjuvant therapy (%) 20 20 15 <.001
Higher-volume surgeon (%) 76 75 92 <.001
Missing 1 1 1
Higher-volume hospital (%) 76 75 88 <.001
Missing 2 2 2
Teaching institution (%) 64 63 84 <.001
Missing 2 2 2
PET, Positron emission tomography. *P value for tests comparing thoracoscopic and open resection. yCalculated among the 1998–2002 cohort.After adjustment, the odds of 30-day death were not sig-
nificantly different when comparing VATS with open resec-
tion, although equivalency was not established based on
noninferiority criteria (Table 3). In models evaluating sur-
vival, the hazards of death for VATS and open resection
were equivalent in the fully adjusted model. In an explor-
atory analysis VATS and open resection were also equiva-
lent in terms of the hazards of lung cancer cause-specific
death (adjusted hazard ratio, 0.99; 95% CI, 0.88–1.11; non-
inferiority bounds, 0.86–1.14). VATS was associated with
a significantly shorter LOS compared with conventional re-
section (adjusted risk difference,5 days; 95% CI,7 to2
days), although Medicare expenditures were not signifi-
cantly different (adjusted risk difference, $290; 95% CI,
$1603 to $2182). Adjustment for all measured variables
(eg, income and education) had no substantial bearing on
any of the findings from the primary analyses. Sensitivity
analyses with 3 different methods of propensity scoring
(ie, adjustment matching, stratification, and regression)
yielded results that were largely similar to those of our pri-
mary analysis.
Finally, a stratified analysis was conducted to explore
whether VATS and conventional resection were equivalent
in terms of survival when performed by different provider
types (Table 4). VATS was at least as effective as conven-
tional resection when performed by higher-volume surgeons
or at higher-volume and teaching hospitals. When per-
formed by lower-volume surgeons or at lower-volume or
nonteaching hospitals, point estimates suggested higher haz-
ards of death associated with VATS, although this apparent
association was not statistically significant.
DISCUSSION
The goals of this investigation were to describe the use
and associated outcomes of VATS resection for lung cancer
and evaluate whether this minimally invasive approach to
pulmonary resection was as safe and effective as the stan-
dard. VATS was infrequently used for cancer management,1418 The Journal of Thoracic and Cardiovascular Sualthough its use increased over time. The risks of early death
after VATS were not significantly different from those after
conventional resection, although equivalency could not be
confirmed. After adjustment, VATS was as effective as con-
ventional resection in terms of long-term survival. VATS
might have been inferior to open resection when performed
by lower-volume surgeons and hospitals.
Several reasons might explain the infrequent use of VATS
for lung cancer management. Surgeons might be uncomfort-
able performing VATS because of insufficient training or
experience with this minimally invasive procedure. Some
surgeons might believe that there is an insufficient level of
evidence to confirm the safety and efficacy of VATS com-
pared with standard resection and might be skeptical about
its purported benefits. In the setting of malignancy in partic-
ular, surgeons might demand higher levels of evidence than
they might for benign conditions. This notion might explain
the relatively slow adoption of a laparoscopic approach to
colon cancer resection,22 despite rapid adoption of laparos-
copy for conditions such as symptomatic cholelithiasis, obe-
sity, and gastroesophageal reflux.23-25 The lack of operating
room resources or staff might also be a barrier to the use of
VATS.
Several lines of evidence support the notion that VATS is
at least as safe as conventional resection. By avoiding rib
spreading, muscle splitting, and the use of a retractor,
VATS is believed to result in less pain, earlier ambulation,
fewer postoperative complications, and possibly fewer early
deaths. Consistent with this claim, several reports show
lower rates of postoperative complications associated with
VATS when compared with conventional resection.1,6,16
Equivalent risks of early death were not demonstrated in
this study for several possible reasons. First, most investiga-
tions, including this one, were probably underpowered to
exclude the possibility of small prespecified differences in
rare events, such as death.26 Alternatively, large variability
in risks of early death might reflect actual variability in out-
comes rather than statistical noise. If true, this explanationrgery c June 2009
Farjah et al General Thoracic Surgery
G
T
Swould suggest that the quality of a VATS procedure is unnec-
essarily variable, perhaps by provider. This possibility could
not be further explored because there were too few events
among the relatively few patients who underwent VATS
by a low-volume surgeon or at a low-volume hospital.
VATS and conventional resection were equivalent in
terms of long-term survival, but 2 caveats are worthy of
mention. A key concern regarding the use of VATS is that
enthusiasm over minimally invasive surgery and its pur-
ported benefits might come at the expense of oncologic prin-
ciples of pulmonary resection: dissecting and ligating
individual bronchovascular structures, obtaining negative
margins, and performing adequate intraoperative staging
of mediastinal lymph nodes. Although it has been demon-
strated that an oncologic resection is possible with
VATS,9,14,22,27 there remains concern that not all surgeons
who perform VATS adhere to these principles. Although
this dataset did not provide an opportunity to evaluate the
appropriateness of a VATS operation, it did allow for indi-
rect examination of clinically important departures from
TABLE 3. Multivariable analysis of safety and effectiveness of VATS
relative to conventional resection
HRsurvival (95% CI)
Equivalence
interval
VATS vs conventional
Unadjusted 0.89 (0.79–0.99)
Add patient
characteristics
0.85 (0.76–0.95)
Add cancer
characteristics
0.91 (0.81–1.02)
Add management
characteristics
0.96 (0.85–1.07)
Add provider
characteristics
0.99 (0.88–1.11)
Adjust for clustering 0.99 (0.90–1.08) 0.89–1.11
OR30-d mortality (95% CI) Equivalence
interval
VATS vs conventional
Unadjusted 0.84 (0.53–1.35)
Add patient
characteristics
0.77 (0.48–1.24)
Add cancer
characteristics
0.81 (0.50–1.31)
Add management
characteristics
0.82 (0.51–1.31)
Add provider
characteristics
0.93 (0.58–1.48)
Adjust for clustering 0.93 (0.57–1.50) 0.72–1.28
Patient characteristics are age, sex, race, and Charlson Comorbidity Index. Cancer
characteristics are histology, stage, and tumor size of greater than 3 cm. Management
characteristics are mediastinoscopy, mediastinal lymphadenectomy, and neoadjuvant
therapy. Provider characteristics are higher-volume surgeon, higher-volume hospital,
and teaching institution. Values are adjusted for clustering at the hospital level. The
hazard ratio (HR) of death is shown. The odds ratio (OR) approximates relative risk
when the outcome is rare. VATS, video-assisted thoracoscopy; CI, Confidence interval.The Journal of Thoracic and Cstandard oncologic principles measured in terms of patient
survival. Even though the overall analysis supported the
equivalence of a VATS approach, stratified analyses sug-
gested higher risks of death associated with VATS when
performed by low-volume surgeons. Although volume
might have been a requisite for achieving equivalent out-
comes with VATS, a more likely explanation is that it was
a surrogate for appropriately performed VATS resections.
The findings from this study are consistent with the notion
that VATS was at least as good as conventional resection
but only to the extent that VATS was performed according
to appropriate oncologic principles. A second caveat is
that this study was not a randomized noninferiority trial
and is therefore subject to the usual limitations of an obser-
vational study, including unmeasured confounding (patient
selection factors known or suspected to affect outcomes
and possibly result in bias).
Findings from this investigation are consistent with
prior descriptions of an association between VATS and
shorter LOS1,3 but challenge the notion that shorter LOS
results in cost savings. Shorter LOS is plausibly explained
by less pain, earlier ambulation, and fewer complications
after a VATS resection,1,6,16 and if true, these benefits
would reasonably be expected to translate into cost sav-
ings. One explanation for why there were no observed
cost savings associated with VATS is that Medicare
expenditures were likely related to an episode of care
(ie, hospitalization for lung cancer resection) rather than
specific attributes of that care, such as type of operation
performed, LOS, or frequency of adverse events. Had
expenditures for subsequent care (beyond the index hospi-
talization) been evaluated and adverse event rates truly
been lower for VATS, then cost savings might have
been observed. Also, although it appears that shorter
TABLE 4. Stratified regression analysis evaluating provider influence
on VATS outcomes
Lower-volume
surgeon
Higher-volume
surgeon
VATS vs conventional
Adjusted HR*
(95% CI)
1.42 (0.94–2.17) 0.96 (0.87–1.06)
Lower-volume
hospital
Higher-volume
hospital
VATS vs conventional
Adjusted HR*
(95% CI)
1.13 (0.84–1.54) 0.97 (0.88–1.07)
Nonteaching
hospital
Teaching
hospital
VATS vs conventional
Adjusted HR*
(95% CI)
1.13 (0.88–1.45) 0.96 (0.87–1.06)
VATS, Video-assisted thoracoscopy; HR, hazard ratio; CI, confidence interval.
*Adjusted for patient, cancer, management, and provider characteristics and cluster-
ing. Equivalence interval ¼ 0.89 to 1.11.ardiovascular Surgery c Volume 137, Number 6 1419
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it is likely that hospitals profited from patients who spent
less time in the hospital. VATS might have been associ-
ated with shorter LOS because surgeons who commonly
perform VATS might also frequently use clinical pathways
and algorithms expediting postoperative care.28 It would
be important to know how much of the association be-
tween VATS and shorter LOS is explained by the use of
such pathways because these algorithms might also be
applicable to patients who undergo open resection. Unfor-
tunately, the limitations of the dataset precluded a more
detailed health economic analysis.
This study had a number of limitations. Because Medicare
claims were created for administrative rather than research
purposes, we were unable to measure important clinical vari-
ables, such as lung function, performance status, and sever-
ity of underlying comorbidities. This might have resulted in
inadequate risk adjustment and possibly biased our noninfer-
iority-based analyses. Although clinical databases, such as
the one maintained by the Society of Thoracic Surgeons,
likely allow for better risk adjustment, the SEER-Medicare
database more likely provides a nationally representative de-
scription of patterns of care and associated outcomes, at least
at this time. Yet even the SEER-Medicare database might be
somewhat limited in its generalizability if patterns of care
and outcomes are different for patients 65 years and younger
or those enrolled in health maintenance organizations or
other health plans. However, because the median age of
lung cancer is 70 years29 and Medicare provides health
care coverage for 97% of elderly Americans, SEER-Medi-
care data might very well be generalizable. Finally, missing
data varied by approach to resection (17% for standard re-
section and 13% for VATS) and might have biased our re-
sults. Because patients with missing covariate data had
lower survival rates (40% vs 45%, P< .001) and were ex-
cluded from the analysis, outcomes associated with the stan-
dard resection group might have been too optimistic in the
case-complete analysis. Any such bias might have resulted
in VATS appearing equivalent to conventional resection
when in truth VATS might have been associated with better
outcomes.
The findings from this study have several implications for
clinical practice, surgical education, policy, and future
research. In counseling patients on the risks and benefits
of pulmonary resection, results from this study can be cited
as additional evidence, limitations notwithstanding, support-
ing the equivalency of VATS and standard resection in terms
of effectiveness. Because there might be variability in VATS
outcomes across surgeons and hospitals, greater efforts
should be taken to mandate standardized VATS training
within cardiothoracic training programs. Additionally, hos-
pitals and organizations might choose to require credential-
ing of surgeons in the appropriate use of VATS. Given the
limitations of this and other studies, future investigations1420 The Journal of Thoracic and Cardiovascular Suwould ideally confirm the equivalence of VATS and stan-
dard resection in a randomized noninferiority trial. The fea-
sibility of such a trial has been questioned on the basis of
sample size and lack of clinical equipoise among individual
surgeons.27 Demonstrating noninferiority in terms of safety
will not likely be feasible because it would require 13,888
patients to demonstrate a 1% difference in 30-day mortality
rates. In contrast, 2982 patients would be needed to demon-
strate a 5% difference in overall survival rates. Given the
high incidence of lung cancer, a multicenter approach might
be a realistic option if equipoise were to exist. The feasibility
of conducting multicenter noninferiority trials in surgical on-
cology has been demonstrated previously in the setting of
operable colon cancer.30 In the interim, prospective observa-
tional studies should aim to re-evaluate the noninferiority of
VATS by using clinical data for risk adjustment and quantify
its purported benefits by using validated metrics for quality
of life and functional status.
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350:2050-9.APPENDIX 1. Billing codes used to define staging and therapy
Resection
HCPCS 32480 32484 32663
Chemotherapy
HCPCS 95549 96400 96404 96406 96410 96412 96414 96420 96420 96422 96423
96425 96440 96445 96450 96542 96545 C9017 J0182 J8510 J8530 J8560
J8610 J899 J9000 J9001 J9010 J9045 J9060 J9062 J9070 J9080 J9090
J9091 J9092 J9093 J9094 J9095 J9096 J9097 J9170 J9180 J9181 J9182
J9190 J9201 J9206 J9208 J9230 J9250 J9260 J9265 J9280 J9290 J9291
J9350 J9360 J9370 J9375 J9380 J9390 J9999 Q0083 Q0084 Q0085 Q0125
Q0127 Q0128 Q0129 S0178 S0182 S9329 S9330 S9331
ICD-9 V58.1 V66.2 V67.2 99.25
RCC 0331 0332 0335
Radiation therapy
HCPCS 31643 77300 77301 77305 77310 77315 77321 77326 77327 77328 77331
77332 77333 77334 77336 77370 77380 77381 77399 77401 77402 77403
77404 77406 77407 77408 77409 77411 77412 77413 77414 77416 77417
77418 77419 77420 77425 77427 77430 77431 77432 77470 77499 77520
77522 77523 77525 77750 77761 77762 77763 77781 77782 77783 77784
77799 C1716 C1717 C1718 C1719 C1720 C1790 C1791 C1792 C1793 C1794
C1795 C1796 C1797 C1798 C1799 C1800 C1801 C1802 C1803 C1804 C1805
C1806 C2616 G0126 G0173
ICD-9 V58.0 V66.1 V67.1 92.20 92.21 92.22 92.23 92.24 92.26 92.27 9.28
92.29 92.30 92.31 92.32 92.33 92.39
PET
HCPCS G0125 G0126 G0210 G0211 G212 G0234 78810
Mediastinoscopy
HCPCS 39400
Mediastinal lymphadenectomy
HCPCS 38746
HCPCS, Healthcare Common Procedure Coding System; ICD-9, International Classification of Diseases, Ninth Revision; RCC, Revenue Center Codes; PET, positron emission
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